ArticleTherapeutic advances in musculoskeletal disease2025
Double positivity for anti-dsDNA and anti-Sm antibodies represents higher disease activity in systemic lupus erythematosus.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies have shown that anti-dsDNA and anti-Sm antibodies not only contribute to the classification of systemic lupus erythematosus (SLE) but also strongly correlate with disease activity. However, the relationship between double positivity for anti-dsDNA and anti-Sm antibodies and disease activity remains unclear. Objectives: This study aimed to assess the clinical significance of double positivity for anti-dsDNA and anti-Sm antibodies in SLE. Design: A single-center retrospective study was conducted, consecutively enrolled hospitalized patients with SLE who underwent anti-dsDNA and anti-Sm antibody testing between June 2009 and December 2022. Methods: In this study, clinical data were collected from the electronic medical records of all study participants. SLE Disease Activity Index 2000 (SLEDAI 2000) scores were calculated; SLEDAI 2000 scores excluding anti-dsDNA scores were defined as modified SLEDAI 2000 (mSLEDAI 2000) scores. Severe disease activity was defined as a SLEDAI 2000 score of >12. Results: The study included 408 patients with SLE; of them, 95 were double-positive for anti-dsDNA and anti-Sm antibodies, 193 were single-positive for anti-dsDNA or anti-Sm antibodies, and 120 were double-negative. The double-positive group showed more clinical manifestations, lower C3 and C4 levels, and higher SLEDAI 2000 and mSLEDAI 2000 scores compared to the double-negative and single-positive groups. During follow-up, double-positive patients, whether converted to single-positive or double-negative, showed a significant decrease in SLEDAI 2000 and mSLEDAI 2000 scores, but the improvement in SLEDAI 2000 scores was not significant in patients with persistent double positivity. In recognizing severe disease activity, double positivity had the highest specificity, positive predictive value, positive likelihood ratio, and highest Youden index, albeit with the lowest sensitivity, compared to anti-dsDNA positivity, anti-Sm positivity, and positivity for anti-dsDNA and/or anti-Sm antibodies. Furthermore, a higher proportion of patients with double positivity were treated with high-dose or shock-dose glucocorticoids. Conclusion: Double positivity for anti-dsDNA and anti-Sm antibodies suggests higher disease activity in patients with SLE who may require more intense immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.